Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid
for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast
cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy
Phase:
Phase 3
Details
Lead Sponsor:
German Breast Group
Collaborators:
Austrian Breast & Colorectal Cancer Study Group Novartis Pharmaceuticals